

PROVIDER NEWSLETTER

A newsletter for Molina Healthcare Provider Networks

First Quarter 2022



In this Issue

| | |
|---|---|
| Consumer Assessment of Healthcare Providers and Systems (CAHPS®)... | 1 |
| Molina Healthcare's 2021 Quality Improvement Results | 2 |
| Requirement for Submitting Prior Authorizations for Molina..... | 3 |
| Strengthening the Primary Care Setting with Trauma-Informed Care .. | 4 |
| Secure Messaging from Claim Status Screen Enabled in Availity Essentials Portal | 5 |
| Clinician Administered Preferred Drug List 2022 | 5 |

Consumer Assessment of Healthcare Providers and Systems (CAHPS®)

The Consumer Assessment of Healthcare Providers and Systems (CAHPS®) is an industry standard survey tool used to evaluate patient satisfaction. Improving patient satisfaction has many benefits. It not only helps to increase patient retention, but can also help increase compliance with physician recommendations and improve patient outcomes.

Focusing together on a positive patient experience will have many important benefits to your practice:

- Increase patient retention
- Increase compliance with physician clinical recommendations
- Improve patient's overall wellness and health outcomes
- Ensure preventive care needs are addressed more timely
- Reduce no show rates

Additional resources are available for office staff and patients:

- For additional after-hours coverage, Molina Healthcare members can call the 24-Hour Nurse Advice Line (888) 275-8750.
- Molina Healthcare members can access Interpreter Services at no cost by calling Member Services (844) 311-9777.
- Providers can access the Provider Web Portal at provider.MolinaHealthcare.com to:
 - Search for patients & check member eligibility

- Submit service request authorizations and/or claims & check status
- Review Patient Care Plan
- Obtain CAHPS® Tip Sheets
- Participate in online Cultural Competency trainings (also available at [MolinaHealthcare.com](https://www.molinahealthcare.com), under Health Resources tab)

Please encourage your patients who have received the CAHPS® survey to participate. Listed below are several questions asked in the survey regarding patient care:

- When you needed care right away, how often did you get care as soon as you needed?
- When you made an appointment for a check-up or routine care at a doctor's office or clinic, how often did you get an appointment as soon as you needed?
- How often was it easy to get the care, tests treatment you needed?
- How often did your personal doctor listen carefully to you?
- How often did your personal doctor spend enough time with you?
- How often did your personal doctor explain things in a way that was easy for you to understand?
- How often did you and your personal doctor talk about all the prescription medicines you were taking?
- How would you rate your personal doctor?

Molina Healthcare's 2021 Quality Improvement Results

Molina Healthcare conducts an annual program evaluation to assess how well we meet the performance goals and objectives for improving the quality and safety of clinical care and services specified within the Quality Improvement Program Description and Annual Work Plan. Below are highlights from the annual evaluation.

CAHPS®

The Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Survey assesses Molina members' satisfaction with their health care. It allows us to better serve our members.

Molina has received the CAHPS® results of how our members rated our providers and our services.

In 2021, Molina achieved the target goal (67th percentile) for the following CAHPS measures: Getting Needed Care, Getting Care Quickly, Rating of Personal Doctor, Rating of Specialist, Rating of Health Care, Coordination of Care and Annual Flu Vaccine.

We need to make improvements in the CAHPS measures pertaining to Rating of Health Plan and Smoking Advice.

HEDIS®



Another tool used to improve member care is the Healthcare Effectiveness Data and Information Set or HEDIS®. HEDIS® scores allow Molina to monitor how many members are receiving the services they need. Measures include immunizations, well-child exams, Pap tests and mammograms. There are also scores for diabetes care, and prenatal and after-delivery care.

In 2021, Molina improved in Colorectal Cancer Screening – Total, Care for Older Adults - Medication Review and Care for Older Adults - Functional Status Assessment.

We need to make improvements in Care for Older Adults - Advance Care Planning, Care for Older Adults - Pain Assessment and Controlling High Blood Pressure.

Culturally and Linguistically Appropriate Services/Disability Resources

Molina also assesses the cultural, ethnic, racial and linguistic needs and preferences of members on an ongoing basis. Information gathered during regular monitoring and annual network assessment is used to identify and eliminate cultural and/or linguistic barriers to care through the implementation of programs and interventions.

Most members specified English as their preferred language (95%). Spanish as a preferred language was identified by 5% of members. Spanish was the most requested language among members through Molina's interpreter services, followed by Russian, Vietnamese and Arabic.

Overall, Molina found that the current Culturally and Linguistically Appropriate Services program resources, structure, and practitioner and community participation are sufficient based on member needs. Additionally, Molina has a series of short Culturally Competency training videos (Health Disparities, LGBTQ+, Immigrants/Refugees, etc.) available on the [Provider Portal](#) and at MolinaHealthcare.com on the Culturally and Linguistically Appropriate Resources/Disability Resources page listed under Health Resources. Disability resources are also available at this location under Molina Provider Education Series: Americans with Disability Act (ADA), Members who are Blind or have Low Vision, Service Animals and Tips for Communicating with People with Disabilities & Seniors.

The progress related to the goals that Molina has set for the annual CAHPS® survey results and the annual HEDIS® measures can be viewed in more detail on the Molina Website. You can also view information about the Quality Improvement Program and print a copy if you would like one. Please visit the provider page on Molina's website at MolinaHealthcare.com.

Requirements for Submitting Prior Authorization for Molina



Molina requires prior authorization (PA) for specific services. Molina offers three tools on the MolinaHealthcare.com website to assist you in knowing what services require Prior Authorization: The PA Code Matrix, the PA Guide, and the PA Code Lookup Tool. Both the PA Code Matrix and the PA Lookup Tool offer detailed information by CPT and HCPCS code regarding PA requirements. The PA

Code Lookup Tool is conveniently located available on the “home” page of Provider area of MolinaHealthcare.com. Check it out here: <https://www.molinahealthcare.com/providers/id/medicaid/home.aspx>. The most efficient prior

authorization submission method is through our Provider Portal provider.MolinaHealthcare.com.

IMPORTANT NOTE: All Pharmacy/Drug Prior Authorization requests should be sent via fax. Do not send via the Provider Portal. The Drug Formulary provides a list of all covered medications and can be found on the Molina website at: www.molinahealthcare.com/providers/id/medicaid/drug/formulary.aspx.

When submitting a prior authorization request, it is important to include all clinical information and medical records necessary to support the medical necessity of the requested service/item. The following is an example of documentation needed:

- Current (up to six months) patient history related to the requested service/item
- Relevant physical examination that addresses the medical need for the requested service(s)
- Relevant lab or radiology results to support the request (include previous MRI, CT, lab or X-ray report/results)
- Relevant specialty consultation notes
- Any other information or data specific to the request showing the member meets the criteria for approving the service/item

By providing all necessary clinical information with the initial request, Molina will be able to make a more timely and complete decision based on the member's current health condition while potentially avoiding a need to request additional supporting documentation. The Urgent/Expedited service request designation should only be used if the treatment is required to prevent serious deterioration in the member's health or could jeopardize their ability to regain maximum function. Requests outside of this definition will be handled as routine/non-urgent. The goal is to have all necessary information submitted with the initial request to make the appropriate decision during the initial review of the service/item and avoid the need for an appeal if the service/item is denied.

NOTE: In the event a denial is issued and subsequently appealed, please be sure to reference the original decision. If the denial was due to missing information needed to justify coverage, not providing that information with your appeal request will not change the decision and could further delay medically necessary covered services/items. Let's work together to ensure timely and appropriate care for your patients.

Strengthening the Primary Care Setting with Trauma-Informed Care

Molina Healthcare is dedicated to promoting the importance of Trauma Informed Practice. According to the National Council for Mental Wellbeing, an "individual's experience of trauma impacts every area of human functioning- physical, mental, behavioral, social, and spiritual." Implementing a Trauma Informed Care approach in the Primary Care setting can benefit providers, members, and office staff alike. The National Council of Mental Wellbeing reports that Trauma-Informed primary care settings can:

- Create safer spaces for staff
- Improve clinical decision-making
- Equip providers to identify and respond to trauma
- Build collaborative care networks to increase provider capacity to address holistic needs

Molina has adopted the guideline for Fostering Resilience and Recovery: A Change Package for Advancing Trauma-Informed Primary Care from The National Council for Mental Wellbeing. For more information, please visit our Clinical Program Guidelines on our provider website or visit the National Council for Mental Wellbeing to access the guideline [here](#).

Secure Messaging from Claim Status Screen Enabled in Availity Essentials Portal

Molina Healthcare strives to offer tools to provider partners so you can get more done with less effort. Molina now offers an integrated messaging feature from the Claim Status screen in the Availity Essentials portal.

You can submit secure messages from the Claim Status screen directly to Molina using Availity's Messaging Application.

Note: You will need the Claim Status and the Messaging App roles to access this function. If you're an administrator for your organization, you can assign roles by selecting Maintain User from your account dashboard. Then, select the user and View/Edit their roles.

Accessing Secure Messaging: Go to Claims & Payments | Claims Status

1. Initiate a message via the "Message this payer" option on the claim status results page. Important: The message must pertain to the current claim listed on the claim status results page.
2. Allow up to two business days for a response.
3. Access the Messaging Queue from the top right corner of your Availity home page.
4. Conversations display as cards. The color of the cards indicates the status.
5. All users have sorting and filtering options. If a message is missing from your queue, clear your filter options

Availity's Messaging App is a faster, more effective platform for resolving simple queries. The next time you have a question about the status of a claim, try messaging.

Customer Support: If you have questions about Messaging from Claim Status, you can reach Availity Client Services at (800) 282-4548 from 7 a.m. to 7 p.m. CT, Monday through Friday.

Additional Questions? We're here to help. Contact your Provider Services Representative or email the Provider Services Team at MHIDProviderSvcReq@MolinaHealthcare.com. For help identifying your Provider Services Representative, visit: MolinaHealthcare.com

Availity Essentials Portal: We continue our transition to the Availity Essentials portal, a tool that streamlines your claims management, authorizations, and eligibility/benefit verification. Are you registered yet? [Click here](#) to get started.

Clinician Administered Preferred Drug List 2022

A clinician-administered drug is an outpatient drug other than a vaccine that is typically administered by a health care provider in a clinician's office or other outpatient clinical setting. For example, drugs that are infused or injected are typically clinician-administered drugs.

The Molina Healthcare, Inc. Medical Preferred Drug List encourages utilization of clinically appropriate and lower net cost products within the following therapeutic drug classes. The

Molina Medical Preferred Drug List includes the listed products only and other product may be available under a plan's medical benefit. The listed preferred products must be used first. An exception process is in place for specific circumstances that may warrant a need for a non-preferred product.

Medicaid Medical Preferred Drug List- Through October 2022

| Drug Class | Non-Preferred Product(s) | Preferred Product(s) |
|---|---|---|
| Alpha-1 Antitrypsin Deficiency | Aralast® (Alpha-1-Proteinase Inhibitor), Glassia® (Alpha-1-Proteinase Inhibitor), Zemaira® (Alpha-1-Proteinase Inhibitor) | Prolastin C® (Alpha-1-Proteinase Inhibitor) |
| Hematologic, Colony Stimulating Factors – Short Acting | Granix® (tbo-filgrastum) Leukine® (sargramostim) Neupogen® (filgrastim) Nivestym® (filgrastim-aafi) | Zarxio® (filgrastim-sndz) |
| Hematologic, Colony Stimulating Factors – Long Acting | Fulphila™ (pegfilgrastim-jmdb), Udenyca® (pegfilgrastim-cbqv), Neulasta® (pegfilgrastim) Nyvepria™ (pegfilgrastim-apgf) | Ziextenzo® (pegfilgrastim-bmez) |
| Infliximab | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Renflexis® (infliximab-abda) Avsola™ (infliximab-axxq) |
| Lysosomal Storage Disorders – Gaucher Disease | VPRIV® (velaglucerase alfa) Elelyso® (taliglucerase alfa) | Cerezyme® (imiglucerase) |
| Multiple Sclerosis (Infused) | Lemtrada® (alemtuzumab) | Tysabri® (natalizumab) Ocrevus® (ocrelizumab) |
| Osteoarthritis, Viscosupplements | Gelsyn-3® (sodium hyaluronate 8.4mg/ml) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis® (hyaluronic acid 8mg/ml) Orthovisc® (1% sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) TriVisc® (sodium hyaluronate) Visco-3® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) | Euflexxa® (1% sodium hyaluronate) |

| | | |
|--|---|---|
| Oncology | **Avastin® (bevacizumab) | Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr) |
| | Herceptin® (trastuzumab) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) | Herzuma® (trastuzumab-pkrb) Kanjinti™ (trastuzumab-anns) Ogivri™ (trastuzumab-dkst) Ontruzant® (trastuzumab-dttb) Trazimera™ (trastuzumab-qyyp) |
| Paroxysmal Nocturnal Hemoglobinuria | Ultomiris® (ravulizumab-cwvz) | Empaveli® (pegcetacoplan) |
| Rituximab | Rituxan® (rituximab) Rituxan Hycela® (rituximab- hyaluronidase) | Truxima® (rituximab-abbs) Ruxience® (rituximab-pvvr) Riabni™ (rituximab-arrx) |
| Retinal Disorders (Eye) | Eylea® (aflibercept) Lucentis® (ranibizumab) | **Avastin® (bevacizumab) |

Marketplace Medical Preferred Drug List- Through October 2022

| Drug Class | Non-Preferred Product(s) | Preferred Product(s) |
|---|---|---|
| Alpha-1 Antitrypsin Deficiency | Aralast® (Alpha-1-Proteinase Inhibitor), Glassia® (Alpha-1-Proteinase Inhibitor), Zemaira® (Alpha-1-Proteinase Inhibitor) | Prolastin C® (Alpha-1-Proteinase Inhibitor) |
| Autoimmune | Actemra® (tocilizumab) IV, Cimzia® (certolizumab pegol), Orencia® (abatacept) | Enyvio® (vedolizumab), Ilumya™ (tilgrakizumab-asmn), Simoni Aria® (golimumab), Stelara® (ustekinumab) |
| Botulinum Toxins | Myobloc® (rimabotulinumtoxin B) | Botox® (onabotulinumtoxin A), Dysport® (abobotulinumtoxin A), Xeomin® (incobotulinumtoxin A) |
| Hematologic, Colony Stimulating Factors – Short Acting | Granix® (tbo-filgrastim) Leukine® (sargramostim) Neupogen® (filgrastim) | Nivestym® (filgrastim-aafi), Zarxio® (filgrastim-sndz) |
| Hematologic, Colony Stimulating Factors – Long Acting | Fulphila™ (pegfilgrastim-jmdb), Udenyca® (pegfilgrastim-cbqv), Nyvepria™ (pegfilgrastim-apgf) | Ziextenzo® (pegfilgrastim-bmez), Neulasta® (pegfilgrastim) |
| Hematologic, Erythropoiesis - Stimulating Agents | Epogen® (epoetin alfa), Mircera® (methoxy polyethylene glycol-epoetin beta), Procrit® (epoetin alfa) | Aranesp® (darbepoetin), Retacrit® (epoetin alfa-epbx) |
| Hemophilia, Factor VIII | Eloctate® (antihemophilic factor recombinant Fc fusion protein), | Adynovate® [antihemophilic factor (recombinant), PEGylated], |

| | | |
|--|---|--|
| | Helixate® [Antihemophilic Factor (Recombinant), Formulated with Sucrose], Nuwiq® [antihemophilic Factor (recombinant)] | Jivi® [antihemophilic factor (recombinant), PEGylated], Kogenate® [antihemophilic factor (recombinant), Kovaltry® [antihemophilic factor (recombinant), Novoeight® [antihemophilic factor (recombinant)] |
| Infliximab | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Renflexis® (infliximab-abda) Avsola™ (infliximab-axxq) |
| Long-Acting Reversible Contraceptives | Liletta® (levonorgestrel-releasing intrauterine system) Nexplanon® (etonogestrel implant) | Kyleena® (levonorgestrel-releasing intrauterine system), Mirena® (levonorgestrel-releasing intrauterine system) Skyla® (levonorgestrel-releasing intrauterine system) |
| Lysosomal Storage Disorders – Gaucher Disease | VPRIV® (velaglucerase alfa) Cerezyme® (imiglucerase) | Elelyso® (taliglucerase alfa) |
| Multiple Sclerosis (Infused) | Lemtrada® (alemtuzumab) | Tysabri® (natalizumab) Ocrevus® (ocrelizumab) |
| Osteoarthritis, Viscosupplements | Gelsyn-3® (sodium hyaluronate 8.4mg/ml) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis® (hyaluronic acid 8mg/ml) Supartz® FX (1% sodium hyaluronate) TriVisc® (sodium hyaluronate) Visco-3® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) | Euflexxa® (1% sodium hyaluronate) Orthovisc® (1% sodium hyaluronate) Monovisc® (sodium hyaluronate) |
| Oncology | NA | Firmagon® (degarelix) |
| | **Avastin® (bevacizumab) | Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr) |
| | Herceptin® (trastuzumab) Herzuma® (trastuzumab-pkrb) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) Trazimera™ (trastuzumab-qyyp) Ontruzant® (trastuzumab-dttb) | Kanjinti™ (trastuzumab-anns) Ogivri™ (trastuzumab-dkst) |
| Paroxysmal Nocturnal Hemoglobinuria | Ultomiris® (ravulizumab-cwvz) | Empaveli® (pegcetacoplan) |

| | | |
|--------------------------------------|--|--|
| Retinal Disorder Agents (Eye) | Eylea®(afibercept) Lucentis® (ranibizumab) | **Avastin® (bevacizumab) |
| Rituximab | Rituxan® (rituximab) Rituxan Hycela®(rituximab-hyaluronidase) | Truxima®(rituximab-abbs) Ruxience®(rituximab-pvvr) Riabni™ (rituximab-arrx) |
| Severe Asthma | Cinqair® (reslizumab) | Dupixent®(dupilumab) Fasenra®(benralizumab) Nucala®(mepolizumab) Xolair® (omalizumab) |